IOVANCE BIOTHERAPEUTICS, INC. (IOVA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 150M 300M 450M Q4 '14: 0 Q1 '15: 0 Q2 '15: 0 Q3 '15: 0 Q4 '15: 0 Q1 '16: 0 Q2 '16: 0 Q3 '16: 0 Q4 '16: 0 Q1 '17: 0 Q2 '17: 0 Q3 '17: 0 Q4 '17: 0 Q1 '18: 0 Q2 '18: 0 Q3 '18: 0 Q4 '18: 0 Q1 '19: 0 Q1 '24: 1.9M Q2 '24: 32.8M Q3 '24: 90.9M Q4 '24: 164.1M Q1 '25: 212.7M Q2 '25: 241.5M Q3 '25: 250.4M Q4 '25: 263.5M Q1 '26: 285.6M Q2 '26: 325M Q3 '15 Q3 '16 Q3 '17 Q3 '18 Q2 '24 Q2 '25 Q2 '26

Gross Profit TTM

0 60M 120M 180M Q4 '24: 56.1M Q1 '25: 69.3M Q2 '25: 80.6M Q3 '25: 82.6M Q4 '25: 90.3M Q1 '26: 112.6M Q2 '26: 157.3M Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-600M -400M -200M 0 200M 400M 600M Q3 '16: -46.2M Q4 '16: -53.6M Q1 '17: -67.5M Q2 '17: -79.4M Q3 '17: -82.7M Q4 '17: -92.9M Q1 '18: -98.9M Q2 '18: -106.7M Q3 '18: -119.4M Q4 '18: -128.3M Q1 '19: -141.4M Q2 '19: -160.2M Q3 '19: -176.7M Q4 '19: -206.9M Q1 '20: -237.7M Q2 '20: -251.2M Q3 '20: -258.5M Q4 '20: -261.9M Q1 '21: -266.7M Q2 '21: -284.5M Q3 '21: -311.8M Q4 '21: -342.7M Q1 '22: -358.8M Q2 '22: -377.2M Q3 '22: -391.3M Q4 '22: -398.9M Q1 '23: -418M Q2 '23: -428.4M Q3 '23: -446.3M Q4 '23: -460.6M Q1 '24: -467.4M Q2 '24: -459.3M Q3 '24: -430M Q4 '24: -395.3M Q1 '25: -398.8M Q2 '25: -410.6M Q3 '25: -416.5M Q4 '25: -403.4M Q1 '26: -363.2M Q2 '26: -301.3M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-600M -400M -200M 0 200M 400M 600M Q3 '16: -45.6M Q4 '16: -52.9M Q1 '17: -66.7M Q2 '17: -78.5M Q3 '17: -81.9M Q4 '17: -92.1M Q1 '18: -97.9M Q2 '18: -105.2M Q3 '18: -116.9M Q4 '18: -123.6M Q1 '19: -134M Q2 '19: -150.9M Q3 '19: -166.6M Q4 '19: -197.6M Q1 '20: -230.2M Q2 '20: -245.7M Q3 '20: -254.8M Q4 '20: -259.6M Q1 '21: -265.4M Q2 '21: -283.8M Q3 '21: -311.3M Q4 '21: -342.3M Q1 '22: -358.4M Q2 '22: -376.4M Q3 '22: -389.9M Q4 '22: -395.9M Q1 '23: -411.7M Q2 '23: -418.8M Q3 '23: -433M Q4 '23: -444M Q1 '24: -449.6M Q2 '24: -440.2M Q3 '24: -410M Q4 '24: -372.2M Q1 '25: -375.4M Q2 '25: -389.9M Q3 '25: -397.6M Q4 '25: -391M Q1 '26: -353.9M Q2 '26: -289.5M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

0 60M 120M 180M Q4 '24: 107.9M Q1 '25: 143.4M Q2 '25: 160.9M Q3 '25: 167.9M Q4 '25: 173.2M Q1 '26: 173M Q2 '26: 167.7M Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating Cash Flow TTM

-450M -300M -150M 0 150M 300M 450M Q3 '16: -27.1M Q4 '16: -32.7M Q1 '17: -46.9M Q2 '17: -60.7M Q3 '17: -69.9M Q4 '17: -78.7M Q1 '18: -77.8M Q2 '18: -84.2M Q3 '18: -90.7M Q4 '18: -101.2M Q1 '19: -112.5M Q2 '19: -122.4M Q3 '19: -136.6M Q4 '19: -158.9M Q1 '20: -195.1M Q2 '20: -197.9M Q3 '20: -196.3M Q4 '20: -205.1M Q1 '21: -202.2M Q2 '21: -219.6M Q3 '21: -236.8M Q4 '21: -227.9M Q1 '22: -239.4M Q2 '22: -263M Q3 '22: -268.9M Q4 '22: -292.8M Q1 '23: -318.8M Q2 '23: -335.1M Q3 '23: -355.5M Q4 '23: -361.8M Q1 '24: -384.3M Q2 '24: -388.8M Q3 '24: -363.7M Q4 '24: -353M Q1 '25: -334.4M Q2 '25: -303.4M Q3 '25: -323.1M Q4 '25: -302.4M Q1 '26: -270.8M Q2 '26: -264.2M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-450M -300M -150M 0 150M 300M 450M Q3 '15: 6.7M Q4 '15: -12.6M Q1 '16: -19.8M Q2 '16: -19M Q3 '16: -28M Q4 '16: -34.2M Q1 '17: -49.2M Q2 '17: -63M Q3 '17: -71.7M Q4 '18: -102.4M Q1 '19: -114.5M Q2 '19: -125.4M Q3 '19: -140.4M Q4 '19: -165.8M Q1 '20: -201.8M Q2 '20: -208.2M Q3 '20: -223.1M Q4 '20: -251.9M Q1 '21: -259.1M Q2 '21: -281.1M Q3 '21: -290.1M Q4 '21: -265.5M Q1 '22: -277.7M Q2 '22: -296.2M Q3 '22: -293.9M Q4 '22: -313.2M Q1 '23: -333.4M Q2 '23: -354.7M Q3 '23: -377.3M Q4 '23: -384.1M Q1 '24: -405.1M Q2 '24: -400.5M Q3 '24: -374.1M Q4 '24: -364M Q1 '25: -347.5M Q2 '25: -323.5M Q3 '25: -351.8M Q4 '25: -336.2M Q1 '26: -305M Q2 '26: -296.4M Q3 '16 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 80M 160M 240M Q3 '20: 146.5K Q1 '21: 147.4K Q2 '21: 153.8M Q3 '21: 155.5M Q1 '22: 157.1M Q2 '22: 157.3M Q3 '22: 157.8M Q1 '23: 213.7M Q2 '23: 224.5K Q3 '23: 245.8K Q1 '24: 266.2K Q2 '24: 284.8K Q3 '24: 303.3K Q1 '25: 322.9K Q2 '25: 334.5K Q3 '25: 364K Q1 '26: 418.5K Q2 '26: 450.2K Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-9.00 -6.00 -3.00 0.00 3.00 6.00 9.00 Q4 '10: -0.02 Q1 '11: -0.03 Q2 '11: -0.18 Q3 '11: -0.24 Q4 '11: -0.34 Q1 '12: 7.06 Q2 '12: 7.21 Q3 '12: 6.42 Q4 '13: -7.63 Q1 '14: -6.46 Q2 '14: -2.36 Q3 '14: -1.81 Q4 '14: -0.48 Q1 '15: -0.51 Q2 '15: -0.56 Q3 '15: -0.61 Q4 '15: -0.61 Q1 '16: -0.61 Q2 '16: -0.70 Q3 '16: -1.69 Q4 '16: -1.77 Q1 '17: -1.96 Q2 '17: -2.10 Q3 '17: -1.30 Q4 '17: -1.41 Q1 '18: -1.39 Q2 '18: -1.36 Q3 '18: -1.37 Q4 '18: -1.28 Q1 '19: -1.27 Q2 '19: -1.31 Q3 '19: -1.35 Q4 '19: -1.58 Q1 '20: -1.83 Q2 '20: -1.92 Q1 '22: -2.29 Q2 '22: -2.39 Q3 '22: -2.47 Q4 '22: -2.48 Q1 '23: -2.40 Q4 '11 Q1 '14 Q2 '15 Q3 '16 Q4 '17 Q1 '19 Q2 '20 Q1 '23

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.